Botulinum Toxin (Therapeutic) Template

Botox/Neurotoxin injection.

RMH: Medical history reviewed/updates

Indication: Indication/diagnosis
TMJ/bruxism.
Gummy smile.
Masseter hypertrophy.
Facial esthetics.

Consent: Consent/PARQ reviewed; signed/dated
Contraindications/allergies: Contraindications/allergies reviewed

Areas treated: Areas treated
Units per area: Units per area
Total units: Total units
Product used: Product used
Dilution/reconstitution: Dilution/reconstitution details
Lot/expiration: Lot/expiration
Needle size: Needle size
Injection map/photos: Sites documented/photos if taken

Procedure:
Injection sites marked.
Skin cleaned.
Injections administered.
Pressure applied.

Complications: None or describe.
Patient tolerance: Tolerance/response.

Post-treatment instructions: Instructions reviewed.
No rubbing injection sites.
Stay upright for 4 hours.
Avoid strenuous activity for 24 hours.
Results expected in: Results expected in

NV: Next visit

Documentation requirements

Therapeutic neurotoxin notes are reviewed in three lenses: (1) scope of practice — does state law permit a dentist to do this for this indication; (2) medical necessity — is the dental rationale documented; and (3) product safety — lot, dose, sites, consent, and adverse-event readiness. All three must be visible on the chart. Without them, a board complaint or malpractice claim has very little to defend.

• Indication / diagnosis — the specific dental or orofacial reason: bruxism with hypertrophy, myofascial TMD, gummy smile with hyperactive LLSAN, post-surgical trismus, etc. State the dental connection explicitly. "Patient request for esthetics" alone, without a dental indication, is cosmetic and falls under different rules in many states.
• Medical history reviewed and updates — note any contraindications screened: pregnancy or breastfeeding (relative contraindication; manufacturer labeling is Pregnancy Category C / not adequately studied), neuromuscular disease (myasthenia gravis, Eaton-Lambert, ALS — absolute contraindication), aminoglycoside or other neuromuscular-blocking medications, infection at injection site, known hypersensitivity to botulinum toxin or albumin, recent neurotoxin treatment elsewhere (additive dose risk).
• Consent / PARQ — separate, signed, and dated neurotoxin consent distinct from any dental procedural consent. Must include: off-label nature of dental use (most therapeutic dental indications are off-label under the FDA approval for the specific brand), expected onset (3-7 days) and duration (typically 3-4 months), risks (asymmetric smile, ptosis, dysphagia if anatomy compromised, bruising, headache, antibody formation with chronic use, treatment failure, paradoxical effects), alternatives (occlusal therapy, PT, splint, no treatment), and that results are not guaranteed.
• Contraindications / allergies reviewed — explicit screening line; document negative.
• Product used — brand and generic (e.g., onabotulinumtoxinA / Botox, incobotulinumtoxinA / Xeomin, abobotulinumtoxinA / Dysport, prabotulinumtoxinA / Jeuveau). Brands are not unit-for-unit interchangeable — Dysport units are roughly 2.5-3x onabotulinumtoxinA units. State which.
• Dilution / reconstitution — saline volume used to reconstitute the vial (e.g., 2.5 mL preservative-free 0.9% NaCl into a 100-unit Botox vial gives 4 U / 0.1 mL). Reconstitution detail is what allows another clinician to reproduce the dosing.
• Lot number and expiration — both required. Lot tracking is the single most-cited deficiency in board reviews of dental neurotoxin records and is the basis for any product-recall response.
• Areas treated and units per area — anatomic site (masseter, temporalis, LLSAN, depressor anguli oris, etc.), laterality (right / left / bilateral), number of injection points per muscle, and units per point. Total units per area should reconcile to the grand total.
• Total units — grand total delivered this visit. Many boards want this on its own line.
• Needle size — typical 30-32 gauge, 0.5 inch (4-13 mm) for facial / orofacial work; longer for masseter (12.7 mm or longer to reach muscle belly). Document the gauge and length.
• Injection map / photos — pre-treatment photos with markings strengthen the record substantially. AAFE-style consent packages include standardized photo views (frontal repose, frontal smile, oblique). At minimum, document the injection sites with anatomic landmarks ("3 points across the masseter inferior third, 2 cm anterior to gonial angle, etc.").
• Procedure narrative — sites marked, skin cleaned (alcohol or chlorhexidine), injections administered slowly and intramuscularly (not subdermal, except LLSAN which is shallow), pressure applied to minimize bruising. Document patient comfort and any topical anesthesia used.
• Patient tolerance — how the patient tolerated the visit; any vasovagal symptoms.
• Complications — none, or describe (bruising, immediate headache, vasovagal episode, hematoma). Treatment-emergent adverse events should be flagged immediately and followed up.
• Post-treatment instructions reviewed — no rubbing or massaging the injection sites for 4 hours, stay upright for 4 hours, avoid strenuous exercise / heat / saunas / facial treatments for 24 hours, expected onset 3-7 days, peak effect at ~14 days, duration ~3-4 months, what symptoms to call about (asymmetry, ptosis, dysphagia, signs of infection).
• Results expected in — typical 3-7 days for onset, 14 days for full effect; document what was discussed.
• Operator identification — who injected, license / DEA / state-specific permit on file.
• Follow-up plan — re-assess at 2 weeks (efficacy and any touch-ups), schedule next dose at 3-4 months if maintenance is the goal.

Default-normal templating ("medical history reviewed, no changes, patient tolerated well") without the unit count, lot number, sites, and consent line is the most common dental-board record deficiency in this category.

Common denial reasons

Because therapeutic dental neurotoxin is rarely insurance-covered, the operative risks here are not so much denials as board, malpractice, and audit exposures. The most common issues:

• Out-of-scope-of-practice complaint. State board action when the indication isn't clearly dental (cosmetic-only Botox in a state that limits dental neurotoxin to therapeutic indications; treatment of areas outside the orofacial complex).
• Missing or inadequate consent. Failure to disclose off-label nature, alternatives, or specific risks (ptosis, dysphagia). The single most common malpractice trigger.
• Lot number not documented. Audit deficiency on board review and inability to respond to manufacturer recall notices.
• Reconstitution not documented. Without dilution detail, dose verification is impossible — board reviewers and plaintiff experts treat this as evidence of poor practice.
• Brand-substitution without documentation. Switching from Botox to Dysport without re-quoting units (Dysport is roughly 2.5-3x by units) — over- or under-dosing follows.
• Inadequate pregnancy / contraindication screening. No documented review of pregnancy, breastfeeding, neuromuscular disease, or concurrent aminoglycosides.
• Cosmetic claim submitted on a dental policy. Some practices have attempted to cross-bill cosmetic neurotoxin under dental codes; insurance fraud allegations have followed. Don't.
• Failure to obtain dental-board-required CE. Some states (varies by year) require specific CE hours in neurotoxin / dermal filler before a dentist may inject; missing CE is grounds for board action even if no patient harm.
• No re-evaluation at 2 weeks. Documented follow-up assessment is the standard of care; absence of it weakens the chart in any adverse-event review.
• Treatment of cosmetic areas outside the orofacial complex. Glabella, forehead, crow's feet, neck — permitted in some states under the dental license, prohibited in others. Treating outside permitted areas is a direct board violation.

Related templates